Vinpocetine is a poorly water soluble weakly basic drug (pK a = 7.1) used for the treatment of several cerebrovascular and cognitive disorders. Since existing formulations exhibit poor bioavailability and scarce absorption, a dosage form with improved pharmacokinetic properties is highly desirable. Cocrystallization represents a promising approach to generate diverse novel crystal forms and to improve the aqueous solubility and in turn the oral bioavailability. In this paper, a novel ionic cocrystal of vinpocetine is described, using boric acid as a coformer, and fully characterized (by means of DSC, solid-state NMR, powder and single crystal XRD, and Powder Dissolution Test). Pharmacokinetic performance was also tested in a human pilot study.
INTRODUCTION
Crystalline forms are the preferred dosage forms for active pharmaceutical ingredients (APIs) for use in drug products. Generally single and multicomponent crystals show superior stability to their amorphous counterparts and their synthesis (crystallization) tends to afford highly pure products that are reproducible and scalable. 1 Moreover, different crystal forms can exhibit different physicochemical properties that will affect the pharmacokinetics of the drug. For these reasons, during the early stages of drug development, novel crystal forms of the API are searched for through screening processes and their physicochemical properties are identified. [2] [3] [4] [5] [6] [7] [8] [9] These novel crystal forms might include polymorphs or multi-component crystal such as salts, solvates, hydrates and, more recently, cocrystals. Cocrystals are solids that are crystalline single phase materials composed of two or more different molecular and/or ionic compounds, generally in a stoichiometric ratio, which are neither solvates nor simple salts. 10 The current attraction to cocrystals as novel crystal forms is attributed to their ability to change key properties of APIs via inclusion of additional molecules through reliable, therefore designable, interactions (i.e. supramolecular synthons) 11 . A large library of potential coformers can be built using databases containing pharmaceutically approved substances such as the GRAS (generally recognized as safe) list for example, which contains ingredients recognized by the United States Food and Drug Administration (FDA) to be safe under specified conditions. These substances can serve as coformers in order to obtain new crystal forms with improved solubility, 12,13 compressibility, 14 or stability 15 that ultimately impact on bioavailability. 16 The main challenge during pharmaceutical cocrystal development is the rational selection of coformers for a particular drug molecule, since it is not realistic to screen the whole chemical catalogue. Following a proven crystal engineering 17 approach, possible coformers can be chosen to form robust supramolecular interactions (synthons) with the desired drug molecule, taking into consideration supramolecular synthon hierarchy. 18 This supramolecular synthesis strategy 11, 19 primarily relies on crystallographic data found in the Cambridge Structural Database (CSD). 20 This approach, however, has yet to offer clear predictions about whether there will be desirable property improvement in the resulting cocrystals, even though efforts have been made to correlate the physicochemical properties of coformers to those of the resulting cocrystals. 21 In particular, amongst pharmaceutical cocrystals, ionic co-crystals have proven to be a viable route to enhance solubility/bioavailability of poorly soluble drugs. 22 Recently, a pharmaceutical ionic cocrystal containing two active ingredients, Entresto™ used to treat chronic heart failure, gained approval from the FDA. 23 The target of this study, vinpocetine (Figure 1 ), is a semisynthetic derivative of the natural alkaloid vincamine, showing a series of pharmacological properties in relation to cerebral circulation and on vascular resistance, particularly in the area of blood vessels. 24 Vinpocetine has been shown to impact the cerebral circulation and metabolism and improve various types of cerebrovascular circulatory disorders such as the cerebral infarction, cerebral hemorrhage, cerebral arteries cirrhosis 25 and for the long term treatment of cognitive disorders and related symptoms. 26 Due to its low aqueous solubility, and extensive first pass metabolism, vinpocetine presents low oral bioavailability (~6.7%) 27, 28 and, as a consequence, its clinical use is limited. In this context the aim of this investigation is to improve the solubility and bioavailability of vinpocetine with an ionic cocrystal.
MATERIALS AND METHODS

Materials
Vinpocetine E.P. grade was a kind gift from Linnea SA (Riazzino-Locarno, CH) with a purity of 99.8% and was used without further purification. 
Crystal Form Characterization
Single-Crystal X-Ray Diffraction
Single-crystal analysis for 1 was performed on a Bruker-AXS D8 QUEST diffractometer (Bruker, Madison, WI, USA) using a micro focus generator of Mo K radiation (λ = = 0.71073 Å) and CMOS PHOTON detector. Data for 1 were collected at 100 K ‡. Lattice parameters were determined from least-squares analysis, and reflections were integrated using SAINT (Bruker, Madison, WI, USA). 29 The structure was solved by direct methods and refined by full matrix least squares based on F 2 using X-Seed software. 30 All non-hydrogen atoms were anisotropically refined. All hydrogen atoms bonded to carbon, nitrogen, and oxygen atoms were placed geometrically and refined with an isotropic displacement parameter fixed at 1.2 times Uq of the atoms to which they were attached. Hydrogen atoms bonded to methyl groups were placed geometrically and refined with an isotropic displacement parameter fixed at 1.5 times Uq of the carbon atoms.
Powder X-ray Diffraction (PXRD)
The cocrystal structure of 1 was characterized using a D8 Bruker X-ray Powder Diffractometer (Bruker, Madison, WI, USA) using Cu K radiation (λ = 1.54178 Å), 40 kV, 40 mA. Data were collected at room temperature on a sample manually ground in an agate mortar. The data were collected over an angular range of 5° to 40° 2θ value in continuous scan mode using a step size of 0.05° 2θ value and a scan rate of 5°/min.
Moreover, a calculated PXRD diffractogram was generated from the single-crystal structure of 1 using Mercury 2.2 (Cambridge Crystallographic Data Centre, Cambridge, UK) and compared with the pattern obtained from the bulk sample.
Differential Scanning Calorimetry (DSC)
Differential Scanning Calorimetry was performed on a PerkinElmer Diamond differential scanning calorimeter (PerkinElmer, Waltham, MA, USA) with a scan range of 25 °C-250 °C, scan rate of 10 °C/min under nitrogen atmosphere.
Solid-state NMR spectroscopy (SSNMR)
Solid-state NMR spectra were recorded with a Bruker Advance II 400 instrument operating at 400.23, 100.64 and 40. 
Powder Dissolution Test (PDT)
Prior to dissolution test, the equilibrium solubility was determined at 25°C adding an excess of powder to 20 ml of 0.2 M KH 2 PO 4 /0.2 M NaOH (pH 7.4) buffer. The equilibration time was found to be 24h. The dissolution experiments of pure vinpocetine and 1 were performed using 100 ml of pH 7.4 buffer since in previous studies 31 it was reported that vinpocetine solubility is highly pH dependent, and is particularly low at intestinal pH values. Each experiment was performed at 37 °C to mimic body temperature. Additionally, the dissolution tests were performed using non-sink conditions to build up the supersaturation, as commonly occurs under finite volume conditions in the gastrointestinal tract, and to allow for possible events such as nucleation, crystallization and precipitation to proceed 32 . Accordingly, at time zero, a suitable amount of sample (pure drug or cocrystal 1) to give 15 mg of active ingredient, was added to 100 ml phosphate buffer at 37 °C. The crystalline materials were previously sieved and only the powder with a particle size between 50 and 70 µm was used during the dissolution experiments.
Each test lasted 5 h, and the uniformity of conditions was constantly ensured by using an impeller at a stirring rate of 200 rpm. The equilibrium solubility and the amount of vinpocetine solubilized at each time point was quantified by the previously described method 33 . Each formulation was tested in triplicate.
In Vivo absorption studies
For the in vivo study six male volunteers aged between 28 and 55 years were chosen. The study was conducted at the University of Trieste, Italy, following the principles of the Declaration of Helsinki and the International Conference on Harmonization Guidelines. Before the study, a written informed consent was signed by each subject. All the volunteers were prohibited to take medicines, following a one week wash out period before the beginning of the present study.
The dose of 10 mg of vinpocetine was administered in a hard gelatin capsule (type 0) with 200 mL of water. After one week of washout period the same procedure was adopted for the test formulation, administering a hard gelatin capsule containing 14 mg cocrystal 1, corresponding to 10 mg of vinpocetine. Blood samples (5 ml) were collected in heparinized tubes at interval times of 0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, and 5 h following capsule administration. The collected samples were immediately separated by centrifugation at 2400 g for 10 min, subsequently frozen and stored at -40°C until assayed.
In this study, apovincaminic acid plasma concentrations were monitored, as suggested in the literature 34 . This choice was made in consideration of the fast metabolic conversion from vinpocetine to apovincaminic acid.
The determination of apovincaminic acid concentration was performed using a previously published HPLC method 34 . The preparation of the samples for HPLC analysis was performed according to the method reported by Hasa et al 33 . Briefly, 600 μl methanol were added to 200 μl plasma, and the resulting mixture was vortexed for 10 min. After centrifugation (2400 g for 6 min), 5 μl of the organic solution was injected.
Pharmacokinetic Analysis
A compartmental pharmacokinetic analysis was performed using ADAPT 5 software 35 . One-and two-compartment models with and without absorption lag-time were evaluated and onecompartment model with absorption lag-time was selected for the analysis based on favorable value of Akaike information criterion. The estimated parameters were absorption (t 1/2Ka ) and elimination (t 1/2Ke ) half-lives, absorption lag time (t lag ) and apparent distribution volume (V d /F).
Bioavailability parameters, including maximum concentration in plasma (C max ), time to maximum concentration (t max ), and area under the plasma concentration-time curve (AUC) were calculated as secondary parameters.
The relative bioavailability after oral administration (Frel) was calculated in Eq. 1:
Descriptive statistics were calculated, and results are reported as means (standard errors). As this was a pilot study, the results were not subjected to any formal statistical test.
RESULTS AND DISCUSSION
The potential coformers to cocrystalize with vinpocetine were selected through a supramolecular synthon approach. Vinpocetine is characterized by a tertiary amine and an ester functions that could both act as H-bond acceptors. Hence molecules with H-bond donor groups, such as alcohols and mildly acidic carboxylic acids could be ideal coformer candidates. With this in mind
we created a coformer library consisting of GRAS listed substances with hydroxyl functions, among which boric acid was included. Initial screening experiments in acetonitrile afforded a vinpocetine boric acid ionic cocrystal (1) in 85% yield. Conversely, grinding and slurry were not successful in cocrystal formation.
Solid-state characterizations including X-ray diffraction, SSNMR and DSC were performed on 1.
X-Ray Diffraction
Single crystal X-ray diffraction (Figure 2) showed that 1 crystallizes in the monoclinic P2 1 space group with two independent vinpocetine molecules per asymmetric unit. The bond distance and residual electron density analysis suggests that the amine function on the two molecules (N11c (8) in graph set notation). These supramolecular units containing inorganic and organic components form alternating layers that align parallel to the ab plane, as shown in Figure 2 . The experimental PXRD pattern of 1 is reported in Figure 3 and showed a series of sharp diffraction peaks in the 2 theta range 5-40°, suggesting the high crystalline nature of the powdered sample.
From Figure 3 it can be also noticed that the experimental PXRD and the calculated patterns of 1 are very similar, indicating absence of significant amounts of impurities.
It must be noted that although the B 5 H 4 O 10 anion is a rather common species reported in over 150 structures in the CSD, only in 8 entries the anion co-crystallizes with B(OH) 3 .
Differential Scanning Calorimetry
The solid-state thermal behavior of pure vinpocetine, pure boric acid and 1 was investigated by means of DSC analysis. The DSC curve of pure boric acid shows two endothermal events ( Figure   4 ), the first being the melt occurring at 148 °C followed by a second slightly sharper endothermal event at 159 °C, possibly due to the loss of water molecules and crystal lattice transformations of the initial boric acid into other forms more stable at higher temperatures. 36 Pure vinpocetine shows a single sharp melting peak at 152 °C, indicating the highly crystalline nature of the sample. Vinpocetine starts to decompose after ca. 200 °C (Figure 4 ). 1 showed a large melting event with a peak at 191°C, which is higher than both pure vinpocetine and boric acid. The broad melting event in the cocrystal, in accordance to some peak broadening showed in experimental PXRD pattern, is possibly due to the different interactions of vinpocetine molecules within the cocrystal lattice (hydrogen-bonded and protonated vinpocetine molecules), a large range of particle size or a less crystalline sample.
Solid-state NMR spectroscopy
The SSNMR characterization can facilitate the determination of the moieties present in the crystal structure, in particular in addressing the question of whether the compound discussed herein should be regarded as a molecular cocrystal or as an ionic cocrystal. The difference is subtle since it depends on the hydrogen position along the O···H···N interaction, i.e. whether it is close to oxygen or to nitrogen. This depends on several factors including the relative values of pKa (but pKa can be misleading as it is evaluated with respect to the solvent, usually water, and does not necessarily correlate in the solid-state) 37 ,38 the crystal packing and the temperature. It has been reported that NMR spectroscopic methods, such as the measurement of 13 C chemical shifts of carboxylic carbon atoms, are good indicators of the protonated state of COOH groups [39] [40] [41] . On the other hand, the 15 N chemical shift is remarkably sensitive to the protonation degree of Hbonded nitrogen atom with shifts at higher or lower frequencies accordingly with the type of nitrogen atom, i.e. whether aromatic or aliphatic [42] [43] [44] [45] [46] [47] . Similar effects are observed upon halogen bond formation or metal coordination [48] [49] [50] [51] [52] [53] which is in agreement with the minor contribution of the lone pair to  p loc removed by quaternization [54] [55] [56] . The 
Powder Dissolution Test
Powder dissolution tests (PDTs) were performed for pure vinpocetine and 1. Pure vinpocetine showed a dissolution profile typical of a poorly soluble drug where concentration of 0.8 mg/L was reached after 5 h (Figure 7 ). Conversely, in 1 a significant improvement of vinpocetine dissolution rate was achieved. Compared to the orginal drug, the dissolution behavior of vinpocetine in 1 appears to be superior both in terms of rate and extent of total drug dissolved during the first 5 hours. 1 reaches a concentration of 1.4 mg/L; near to the value for pure vinpocetine Cs, 1.6 mg/L ( Figure 7 ). It is worth noting that the Cs value for pure vinpocetine was reached after 24 hours of dissolution analysis (using the same experimental conditions as the powder dissolution analyses), and is consistent with other values previously reported in literature. 31 The fact that 1 dissolves at a much faster rate than vinpocetine is promising and a faster in vivo absorption is expected. In this case the innovative approach of an ionic cocrystallization permits a great improvement of solubilization kinetics with respect to pure crystalline vinpocetine, which can be attributed to different lattice and solvation energies.
In Vivo absorption studies
Inspired by these promising in vitro dissolution profiles, an in vivo pilot study in humans was carried out. A single oral dose of pure vinpocetine was administered to six male volunteers.
Following a one week wash out period, the volunteers were then dosed with 1. The plasma profiles are presented in Figure 8 whilst the pharmacokinetic parameters are listed in Table 3 .
Our results demonstrate an increase in apovincaminic acid concentration corresponding to improved vinpocetine absorption. In fact, it appears that 1 is more rapidly absorbed, showing a shorter t 1/2Ka and t max, and higher C max . In addition to the increased absorption rate, we observed approximately 2-fold improvement in the extent of vinpocetine absorption (Frel). Collectively, these results demonstrate that the improved solubilization kinetics is reflected in an enhanced bioavailability.
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CONCLUSIONS
In summary, we report herein the first ionic cocrystal of vinpocetine, an active ingredient indicated for the improvement of cerebral circulation. As an ionic cocrystal, vinpocetine showed significantly improved dissolution performance with respect to pure vinpocetine. Additionally, the results obtained from the pilot human pharmacokinetic study reveal that the oral bioavailability of vinpocetine is doubled when administered as 1. This study suggests that cocrystallization can be a potential solution to the solubility and bioavailability problems that have thwarted the development of vinpocetine as an effective treatment option for its numerous potential clinical indications. Moreover, these results further verify that cocrystallization is a promising methodology for achieving the desired physicochemical properties of a compound in humans and that these improvements can lead to enhanced bioavailability when applied to compounds that are limited by their solubility. 
